SANDY, Utah, Feb. 4, 2013 /PRNewswire/ -- Rafarma Pharmaceuticals, Inc. (the "Company") OTC symbol (RAFA) announced that it has received the general license for pharmaceutical products and has started the manufacturing of 3 new products.  The general license was one of the final steps required to open the new plant in Terbuniy.  The Company is now in operation and is expected to rapidly increase to 100% capacity of the Terbiniy facility with the addition of government contracts provided by being 1 of 4 National Strategic Pharmaceutical Suppliers to the Russian Federation.

The new products are Sodium Para-Aminosalicilate, Ibuprofen, and Betagistin.  Sodium Para-Aminosalicilate is a tablet with a time release cover. The current dosage manufactured is 1000 mg and is designed to be of use against various forms of tuberculosis. Sodium Para-Aminosalicilate can also be used in conjunction with other anti-tuberculosis medications.  The Ibuprofen manufactured is Rectal Suppositories for children and the currently manufactured dosage is 60 mg.  Betagistin Tablets are manufactured in dosages of 8 mg, 16 mg and 24 mg. The product is used to treat Manier Syndrome which is characterized by drowsiness, nausea, reduction in hearing abilities and noise in the ears. It is also used as treatment of vestibular vertigo.

Julia Andrushkova, a company spokesperson, was quoted as saying:  "Receiving the general license for pharmaceutical products has been a major step to success for the many people involved, and for the Company in general."

Safe Harbor Statement 
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate,"  "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.

SOURCE Rafarma Pharmaceuticals, Inc.